<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401739</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-AML-06-26</org_study_id>
    <nct_id>NCT00401739</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I Study of CSL360 in Patients With Relapsed, Refractory or High-Risk Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
      uncontrolled proliferation of the myeloid line of white blood cells and impaired production
      of normal blood cells. If untreated, patients die of infection or bleeding usually in a
      matter of weeks. CSL360 is a neutralising monoclonal antibody which is believed to target the
      cells that are thought to drive AML but that are not effectively killed by standard
      treatment. The aims of the study are to determine a biologically active dose of CSL360 and
      generate understanding of a rational schedule of administration for future studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, pharmacokinetics</measure>
    <time_frame>September 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>September 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial, complete and overall response</measure>
    <time_frame>September 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological activity</measure>
    <time_frame>September 2009</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with CSL360</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSL360</intervention_name>
    <description>Weekly IV Infusion. Dose escalation study.</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of acute myeloid leukemia

          -  Recent bone marrow biopsy

          -  Prior treatment or medically unfit for standard therapy

        Exclusion Criteria:

          -  Peripheral blood blast count &gt; 30 x 109/L, or rapidly progressive AML

          -  Previous solid organ transplant

          -  Active GvHD or immunosuppression

          -  Concurrent treatment with other anti-cancer therapy

          -  Active infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Roberts, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical &amp; Veterinary Science</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2006</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Russell Basser</name_title>
    <organization>CSL Limited</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

